

From: [REDACTED] (GROW)
Sent: Wednesday 14 February 2024 10:48
To: [REDACTED]
Cc: GROW F1
Subject: RE: Invitation: 5 March MedTech Europe meeting on PFAS - Brussels

Follow Up Flag: Follow up
Flag Status: Flagged

Categories: [REDACTED]

Dear [REDACTED]


Thanks for the invitation and I highly appreciate you have active contributions to the restriction dossier as submitted by Germany, the Netherlands, Denmark, Sweden and Norway during the consultation organized by the European Chemicals Agency (ECHA). ECHA will carefully assess all information received during this consultation. ECHA will communicate when and how they will organize the discussion on those uses in the Committee meetings.

Once the opinion of ECHA's scientific committees is available, a meeting with MedTech, could be useful to address potential remaining concerns.



European Commission

DG for Internal Market, Industry, Entrepreneurship and SMEs
REACH



Follow us on
Facebook: [EU Growth](#)
Twitter: [@EU Growth](#)
Our Websites: ec.europa.eu/growth

From: [REDACTED] <[\[REDACTED\]@medtecheurope.org](mailto:[REDACTED]@medtecheurope.org)>
Sent: Monday, February 12, 2024 9:11 AM

To: [REDACTED]@ec.europa.eu>

Subject: Invitation: 5 March MedTech Europe meeting on PFAS - Brussels

Dear [REDACTED]

I hope this e-mail finds you well.

We are reaching out to you on behalf of MedTech Europe, with an invitation to join our meeting on the morning of 5 March, with our members, to exchange on the Universal PFAS REACH Restriction dossier.

[MedTech Europe](#) is the European trade association that represents manufacturers of medical devices and *in vitro* diagnostic devices (IVDs). We have played an active part in the consultations on the PFAS restriction dossier over the past years and continue to monitor it closely, as PFAS are used in many of our technologies due to their unique combination of properties.

We are extending this invitation to you to have an exchange on the latest status and your views on the file (discussion of ~30-45 minutes). We would be happy to meet you physically in Brussels, at the meeting venue: Thon Hotel EU, but we also have a dial-in as an option if you are not able to join physically.

In the attachment, you may find our position paper which can already give you insights into our views.

Please let us know if you are available for this meeting, we look forward to your reply.

Kind regards,

[REDACTED]

[REDACTED]
Mob. [REDACTED]



EU Transparency Register Number: 433743725252-26
www.medtecheurope.org

